Monoclonal antibodies (mAbs) have become one of the most important classes of
biopharmaceutical products, and they continue to dominate the universe of …

Over the last 3 decades, monoclonal antibodies have become the most important class of
therapeutic biologicals on the market. Development of therapeutic antibodies was …

The ERBB family of receptor tyrosine kinases has a central role in the tumorigenesis of many
types of solid tumour. Various therapeutics targeting these receptors have been approved …

The epidermal growth factor receptor (EGFR) has been shown to be a valid cancer target for
antibody‐based therapy. At present, several anti‐EGFR monoclonal antibodies have been …

The epidermal growth factor receptor (EGFR) is implicated in human cancers and is the
target of several classes of therapeutic agents, including antibody-based drugs. Here, we …

Ab-dependent cellular cytotoxicity (ADCC) is usually considered an important mechanism of
action for immunotherapy with human IgG1 but not IgG2 Abs. The epidermal growth factor …

Epidermal growth factor receptor (EGFR) and its most common extracellular mutant,
EGFRvIII, are important therapeutic targets in multiple cancer types. A number of monoclonal …

Epidermal growth factor receptor variant III (EGFRvIII) seems to constitute the perfect
therapeutic target for glioblastoma (GB), as it is specifically present on up to 28–30% of GB …

Recombinant antibodies such as nanobodies are progressively demonstrating to be a valid
alternative to conventional monoclonal antibodies also for clinical applications. Furthermore …

The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein that is part of
the family of tyrosine kinase receptors. The binding of EGFR to its cognate ligands leads to …